Endometrial cancer test WID®-easy
An innovative epigenetic methylation test that reliably assesses the risk of endometrial cancer. The test has an exceptionally high negative predictive value and helps avoid invasive diagnostic procedures.
Assessing endometrial cancer risk without surgical intervention
Approximately 10% of menopausal women investigated for bleeding are diagnosed with endometrial cancer. While ultrasound or surgical investigations are most commonly used, modern epigenetics offers an alternative – reliably assessing risk using only a vaginal mucosal swab. The WID®-easy methylation test detects specific cancer-related DNA changes and helps avoid unnecessary invasive procedures.
How does the WID®-easy test work?
WID®-easy is an advanced epigenetic test that analyses specific DNA methylation changes characteristic of cancer cells. These changes indicate whether malignant processes may be occurring in the endometrium. The test is performed using polymerase chain reaction (PCR), and results are provided within 2–4 weeks. This enables timely, reliable risk assessment and reduces the need for invasive procedures.
Detects cancer-cell DNA methylation markers
99.7% negative predictive value
Based on an advanced PCR method
Requires only a vaginal mucosal swab
Suitable as a screening tool for patients with unexplained peri- or postmenopausal bleeding
Reliable prevention – without surgery or long waiting times
WID®-easy makes it possible to assess endometrial cancer risk safely and quickly from a simple vaginal swab. It helps avoid unnecessary invasive testing and provides faster reassurance – or enables timely next steps when needed.
Less invasiveness, more peace of mind
Instead of hysteroscopy or endometrial curettage, a vaginal mucosal swab is sufficient – no pain, no anaesthesia, and no lengthy recovery.
Exceptionally high negative predictive value – 99.7%
The test is highly reliable in ruling out endometrial cancer risk, meaning less stress and fewer invasive procedures.
Lower rate of false-positive results
Compared with ultrasound, WID®-easy produces fewer false positives, reducing the number of unnecessary follow-up tests.
An evidence-based solution
The test is based on epigenetic biomarkers and performed using PCR – reliability aligned with modern diagnostics.
When and for whom is the test recommended?
For postmenopausal women experiencing vaginal bleeding
WID®-easy helps rule out – or identify – endometrial cancer risk without invasive procedures.
When ultrasound findings are insufficient
If ultrasound results are unclear, WID®-easy can be a complementary, fast, and safe option.
For patients for whom invasive procedures are stressful or medically risky
The test helps avoid anaesthesia, surgical intervention, and longer recovery times.
For clinicians seeking a reliable screening tool
Well-suited as a first-step test to support decisions on whether further intervention is necessary.
“With the WID-easy test from a simple vaginal swab, around 90% of women could avoid unpleasant invasive diagnostic procedures without increasing the risk of missing cancer.”
WID®-easy reliability: accuracy and quality metrics
The WID®-easy test is based on epigenetic biomarkers and an advanced PCR method, enabling highly accurate exclusion of endometrial cancer. This is supported by scientific research and clinical practice.
99.7% negative predictive value
<48 hours – result turnaround time
Reliable endometrial cancer prevention
Take the WID®-easy test and get a reliable answer without surgical intervention.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
WID®-easy is an additional non-invasive screening tool that helps refine transvaginal ultrasound findings. It is particularly useful when sonography provides an unclear result. The test is performed on a vaginal swab using real-time PCR and evaluates methylation levels of the ZSCAN12 and GYPC genes.
According to study data, ultrasound produced an unclear result in 151 out of 399 cases, whereas WID®-easy did so in only 9 out of 399. In sonography, using a 3 mm endometrial thickness cut-off, as many as 52.6% of women would receive a false-positive result. WID®-easy’s false-positive rate is only 2.6%, while maintaining high detection of true-positive cases.
WID®-easy demonstrates 90.9% sensitivity, 97.3% specificity, and a 99.7% negative predictive value (NPV). The positive predictive value (PPV) is 50%, whereas sonography PPV is only 5%. This means WID®-easy more reliably distinguishes patients who truly need further invasive diagnostics.
Thanks to its high accuracy, WID®-easy helps reduce unnecessary invasive procedures such as endometrial biopsy, hysteroscopy, or curettage. It can be used as a reliable screening step before deciding on surgical intervention.
